Results 41 to 50 of about 21,169 (256)

Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2021
We present a case of metastatic prostate cancer with rare metastases involving the brain and orbit, in addition to liver, skeletal and nodal metastases. The patient had undergone prior hormonal therapy and chemotherapy and had disease progression despite
Ashwin Singh Parihar, Kunal Chandekar, Harpreet Singh, Ashwani Sood, Bhagwant Mittal   +4 more
doaj   +1 more source

Detection rates of recurrent prostate cancer : 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET/CT scans. A systematic review [PDF]

, 2019
Background: The aim of this work was to assess the use of prostate-specific membrane antigen (PSMA)-labelled radiotracers in detecting the recurrence of prostate cancer.
Chaplin, Brian, KandaSwamy, Gokul Vignesh, Lane, Tim, Moghul, Masood, Peedell, Clive, Rai, Bhavan Prasad, Somani, Bhaskar, Vasdev, Nikhil   +7 more
core   +2 more sources

Prostate Cancer Nodal Staging: Using Deep Learning to Predict 68Ga-PSMA-Positivity from CT Imaging Alone [PDF]

, 2020
Lymphatic spread determines treatment decisions in prostate cancer (PCa) patients. 68Ga-PSMA-PET/CT can be performed, although cost remains high and availability is limited.
Amthauer, Holger, Baur, Alexander D. J., Brenner, Winfried, Furth, Christian, Hamm, Bernd, Hartenstein, Alexander, Lübbe, Falk, Makowski, Marcus, Penzkofer, Tobias, Rudolph, Madhuri M.   +9 more
core   +1 more source

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives [PDF]

, 2018
Gallium prostate specific membrane antigen (PSMA) ligand positron emission tomography (PET) is an increasingly used imaging modality in prostate cancer, especially in cases of tumor recurrence after curative intended therapy.
Baur, Alexander D. J., Beck, Marcus, Belka, Claus, Cihoric, Nikola, Combs, Stephanie E., Debus, Jürgen, Ganswindt, Ute, Ghadjar, Pirus, Grosu, Anca Ligia, Guckenberger, Matthias, Habl, Gregor, Hölscher, Tobias, Koerber, Stefan Alexander, Kroeze, Stephanie, Lohaus, Fabian, Wust, Peter, Zamboglou, Constantinos, Zschaeck, Sebastian, Zöphel, Klaus   +18 more
core   +4 more sources

Prostate-Specific Membrane Antigen-Based Therapeutics

Advances in Urology, 2012
Prostate cancer (PC) is the most common noncutaneous malignancy affecting men in the US, leading to significant morbidity and mortality. While significant therapeutic advances have been made, available systemic therapeutic options are lacking.
Naveed H. Akhtar, Orrin Pail, Ankeeta Saran, Lauren Tyrell, Scott T. Tagawa   +4 more
doaj   +1 more source

DNA vaccination for prostate cancer: key concepts and considerations [PDF]

, 2015
While locally confined prostate cancer is associated with a low five year mortality rate, advanced or metastatic disease remains a major challenge for healthcare professionals to treat and is usually terminal. As such, there is a need for the development
A Ghosh, A Horwich, A Schietinger, A Thakur, A Yoshida, A-C Durieux, A-K Roos, AB Raff, AC Cunha, AD Frankel, AI Daud, B Ferraro, B Schurko, C. R. UK, CM Fehres, CW Pouton, D Escors, D Yang, D Zhang, DG McNeel, DG McNeel, DM Copolovici, DM Lubaroff, DS Coffey, E Rosenbaum, EF Boudreau, F Eriksson, F Kong, F Saad, G Dom, H Davtyan, H Hosseinkhani, H Lv, H-L Jiang, H-S Jeong, HO McCarthy, HO McCarthy, J Rice, JC Glorioso, JD Wolchok, JL Coll, JM Ottnod, JP Eder, K Oosterhuis, K Zhang, L Chudley, L Fong, LE Johnson, LE Johnson, LE Johnson, M Breunig, M Duvshani-Eshet, M Krupa, M Mahadevan, M Mincheff, M Noguchi, M Pavlenko, M Yoshida, MA Kutzler, MD Brown, MDLL Garcia-Hernandez, ME Martin, MI Milowsky, MT Lin, N Agarwal, N Gao, N Tatsis, NW Kim, NY Sardesai, P Castelo-Branco, PD Gregor, PW Kantoff, PW Kantoff, R Suzuki, R Truant, RA Madan, RB Moss, RB Sims, RS Hubert, S Aggarwal, S Ahmad, S Daya, S Drunen Littel-van den Hurk, S Drunen Littel-van van, S Jones, S Kawakami, S Kim, S Kim, S Mehier-Humbert, S Slovin, S-H Min, S-O Choi, SP Balk, SP Vyas, T Yuan, TJ Graddis, WT Godbey, X Sun, X Zhang, Y Lu, Y Yamashita, Y Yi   +101 more
core   +1 more source

Pretherapeutic PSMA PET-Derived Semiquantitative Parameters as Predictors of PSA Response in Patients with mCRPC Receiving [¹⁷⁷Lu]Lu-PSMA-617 Radioligand Therapy

Indian Journal of Radiology and Imaging
Objective [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 radioligand therapy (RLT) shows promise for metastatic castration-resistant prostate cancer (mCRPC) patients with positive PSMA positron emission tomography (PET) imaging ...
Dheeratama Siripongsatian, Attapon Jantarato, Chetsadaporn Promteangtrong, Anchisa Kunawudhi, Peerapon Kiatkittikul, Natphimol Boonkawin, Sukanya Yaset, Sirinsuda Somboon, Chanisa Chotipanich   +8 more
doaj   +1 more source

Towards a Precision Medicine Approach and In Situ Vaccination against Prostate Cancer by PSMA-Retargeted oHSV

Viruses, 2021
Prostate specific membrane antigen (PSMA) is a specific high frequency cell surface marker of prostate cancers. Theranostic approaches targeting PSMA show no major adverse effects and rule out off-tumor toxicity.
Andrea Vannini, Federico Parenti, Daniela Bressanin, Catia Barboni, Anna Zaghini, Gabriella Campadelli-Fiume, Tatiana Gianni   +6 more
doaj   +1 more source

DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand? [PDF]

, 2012
Development of various vaccines for prostate cancer (PCa) is becoming an active research area. PCa vaccines are perceived to have less toxicity compared with the available cytotoxic agents.
Gerald C Sullivan, Mark Tangney, Paul Sweeney, Sarfraz Ahmad   +3 more
core   +1 more source

PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) AS DIAGNOSTIC BIOMARKER IN PROSTATE CANCER

Indonesian Journal of Urology, 2022
Objective: This study aimed to compare PSMA expression in both prostate cancer and benign prostate disease. Material & Methods: PSMA antigen expression was examined using polymerase chain reaction (PCR), twenty samples from each prostate cancer and benign prostate group were examined at the Department of Pathology Anatomy, Sardjito General Hospital.
Lucky Frannata, Indrawarman Soeroharjo, Raden Danarto, Didik Setyo Heriyanto   +3 more
openaire   +2 more sources